Title:
NASAL VACCINE
Document Type and Number:
WIPO Patent Application WO/2006/107097
Kind Code:
A1
Abstract:
A nasal vaccine capable of inducing an effective immunoreaction in the nasal cavity is provided. Specifically, a nasal vaccine comprising a compound having an action of NKT cell activation, particularly, a compound such as (2S,3S,4R)-1-(&agr -D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol represented by the formula (I): (I) (wherein R represents an aldopyranose residue; X’ represents an oxygen atom, a sulfur atom or -NH-; M represents an integer of 0 to 26; n represents an integer of 0 to 16; p represents an integer of 0 to 4; and Me represents a methyl group), or the formula (II): (II) and an immunogen in an amount effective in stimulating an immune response is provided.
Inventors:
SEINO KEN-ICHIRO (JP)
TANIGUCHI MASARU (JP)
TASHIRO TAKUYA (JP)
FUHSHUKU KEN-ICHI (JP)
MORI KENJI (JP)
HASEGAWA HIDEKI (JP)
TANIGUCHI MASARU (JP)
TASHIRO TAKUYA (JP)
FUHSHUKU KEN-ICHI (JP)
MORI KENJI (JP)
HASEGAWA HIDEKI (JP)
Application Number:
PCT/JP2006/307281
Publication Date:
October 12, 2006
Filing Date:
March 30, 2006
Export Citation:
Assignee:
RIKEN (JP)
TIONAL INST OF INFECTIOUS DISE (JP)
SEINO KEN-ICHIRO (JP)
TANIGUCHI MASARU (JP)
TASHIRO TAKUYA (JP)
FUHSHUKU KEN-ICHI (JP)
MORI KENJI (JP)
HASEGAWA HIDEKI (JP)
TIONAL INST OF INFECTIOUS DISE (JP)
SEINO KEN-ICHIRO (JP)
TANIGUCHI MASARU (JP)
TASHIRO TAKUYA (JP)
FUHSHUKU KEN-ICHI (JP)
MORI KENJI (JP)
HASEGAWA HIDEKI (JP)
International Classes:
A61K45/00; A61K9/08; A61K9/12; A61K9/19; A61K31/7052; A61K31/7056; A61K39/09; A61K39/145; A61K39/21; A61K39/215; A61K39/36; A61K39/39; A61P31/04; A61P31/16; A61P31/18; A61P43/00; C07H15/26
Domestic Patent References:
| WO2003016326A1 | 2003-02-27 | |||
| WO1998044928A1 | 1998-10-15 |
Foreign References:
| JPH09315980A | 1997-12-09 |
Other References:
BRADNEY C.P. ET AL.: "Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization", JOURNAL OF VIROLOGY, vol. 76, no. 2, 2002, pages 517 - 524, XP003005884
GONZALEZ-ASEQUINOLAZA G. ET AL.: "Natural Killer T Cell Ligand alpha-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines", J. EXP. MED., vol. 195, no. 5, 2002, pages 617 - 624, XP003005885
TSUJI M.: "Malaria no Atarashii Men'eki Kijo-NKT Saibo no Kanyo-", KANSEN ENSHO MEN'EKI, vol. 32-4, 2002, pages 232 - 239, XP003005886
KAWANO T. ET AL.: "CD1d-Restricted and TCR-Mediated Activation of Valpha14 NKT Cells by Glycosylceramides", SCIENCE, vol. 278, 1997, pages 1626 - 1629, XP002175772
NAKANISHI K.: "IL-18 ni yoru Th1/Th2 Men'eki Oto no Chosetsu", IGAKU NO AYUMI, vol. 207, no. 4, 2003, pages 237 - 243, XP003005887
See also references of EP 1872794A4
GONZALEZ-ASEQUINOLAZA G. ET AL.: "Natural Killer T Cell Ligand alpha-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines", J. EXP. MED., vol. 195, no. 5, 2002, pages 617 - 624, XP003005885
TSUJI M.: "Malaria no Atarashii Men'eki Kijo-NKT Saibo no Kanyo-", KANSEN ENSHO MEN'EKI, vol. 32-4, 2002, pages 232 - 239, XP003005886
KAWANO T. ET AL.: "CD1d-Restricted and TCR-Mediated Activation of Valpha14 NKT Cells by Glycosylceramides", SCIENCE, vol. 278, 1997, pages 1626 - 1629, XP002175772
NAKANISHI K.: "IL-18 ni yoru Th1/Th2 Men'eki Oto no Chosetsu", IGAKU NO AYUMI, vol. 207, no. 4, 2003, pages 237 - 243, XP003005887
See also references of EP 1872794A4
Attorney, Agent or Firm:
Takashima, Hajime (1-1 Fushimimachi 4-chome, Chuo-k, Osaka-shi Osaka, JP)
Download PDF: